Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 10/20 | 1.00 |
| ▸ | MAPT | P10636 | 11/20 | 0.80 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.80 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.80 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.80 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.80 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.80 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.77 |
| ▸ | HTT | P42858 | 3/20 | 0.77 |
| ▸ | GAA | P10253 | 2/20 | 0.77 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.76 |
| ▸ | POLB | P06746 | 2/20 | 0.65 |
| ▸ | HPGD | P15428 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2481061 | 0.89 | MAPT (0.86) | HTR6MAPTCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL2482884 | 0.89 | HTR6 (1.00) | HTR6MAPTCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL2482386 | 0.89 | HTR6 (1.00) | HTR6MAPTCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL475688 | 0.88 | HTR6 (0.79) | HTR6MAPTCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL475542 | 0.88 | HTR6 (0.78) | HTR6MAPTCYP1A2CYP2C9CYP2C19 | |
| Hydrochloric Acid SCHEMBL1748431 | 0.87 | HTR6 (0.77) | HTR6MAPTCYP1A2CYP2C9CYP2C19 | |
| Hydrochloric Acid SCHEMBL1748802 | 0.87 | HTR6 (0.77) | HTR6MAPTCYP1A2CYP2C9CYP2C19 | |
| Hydrochloric Acid SCHEMBL2680318 | 0.87 | HTR6 (0.77) | HTR6MAPTCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL2481118 | 0.87 | MAPT (1.00) | HTR6MAPTCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL1748540 | 0.86 | HTR6 (0.84) | HTR6MAPTCYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1851210-B1 | NITRO-SUBSTITUTED PHENYL-PIPERAZINE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS | ESTEVE LABOR DR (ES) | 2011-10-19 | — | — | EP | claimed |
| US-20080176854-A1 | Nitro-Substituted Phenyl-Piperazine Compounds, Their Preparation and Use in Medicaments | LABORATORIOS DEL DR. ESTEVE S.A (ES) | 2008-07-24 | — | — | US | claimed |
| EP-1851210-A2 | NITRO-SUBSTITUTED PHENYL-PIPERAZINE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-11-07 | — | — | EP | claimed |
| WO-2006069808-A2 | NITRO-SUBSTITUTED PHENYL-PIPERAZINE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-07-06 | — | — | WO | claimed |
| EP-1676842-A1 | Nitro-substituted phenyl-piperazine compounds, their preparation and use in medicaments | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-07-05 | — | — | EP | claimed |
| CN-102170882-B | Compositions and methods of treating amyloid disease | TREVENTIS CORP | 2014-04-02 | — | — | CN | disclosed |
| US-8420640-B2 | Methods of treating amyloid disease using analogs of 1-(4-nitrophenyl) piperazine | TREVENTIS CORPORATION (US) | 2013-04-16 | — | — | US | disclosed |
| EP-1851210-B1 | NITRO-SUBSTITUTED PHENYL-PIPERAZINE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS | ESTEVE LABOR DR (ES) | 2011-10-19 | — | — | EP | disclosed |
| US-20110218200-A1 | METHODS OF TREATING AMYLOID DISEASE USING ANALOGS OF 1-(4-NITROPHENYL) PIPERAZINE | TREVENTIS CORPORATION | 2011-09-08 | — | — | US | disclosed |
| EP-2320897-A1 | COMPOSITIONS AND METHODS OF TREATING AMYLOID DISEASE | Treventis Corporation (US) | 2011-05-18 | — | — | EP | disclosed |
| US-20100120747-A1 | COMBINATION OF A CHOLINESTERASE INHIBITOR AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-05-13 | — | — | US | disclosed |
| US-20100074955-A1 | Combination of NMDA-Receptor Ligand and a Compound With 5-HT6 Receptor Affinity | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-03-25 | — | — | US | disclosed |
| EP-2040755-A1 | COMBINATION OF A CHOLINESTERASE INHIBITOR AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2009-04-01 | — | — | EP | disclosed |
| US-20080176854-A1 | Nitro-Substituted Phenyl-Piperazine Compounds, Their Preparation and Use in Medicaments | LABORATORIOS DEL DR. ESTEVE S.A (ES) | 2008-07-24 | — | — | US | disclosed |
| WO-2008034815-A1 | COMBINATION OF NMDA- RECEPTOR LIGAND AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-03-27 | — | — | WO | disclosed |
| EP-1902733-A1 | Combination of a NMDA-receptor ligand and a compound with 5-HT6 receptor affinity | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-03-26 | — | — | EP | disclosed |
| WO-2007147883-A1 | COMBINATION OF A CHOLINESTERASE INHIBITOR AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-12-27 | — | — | WO | disclosed |
| EP-1851210-A2 | NITRO-SUBSTITUTED PHENYL-PIPERAZINE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-11-07 | — | — | EP | disclosed |
| WO-2006069808-A2 | NITRO-SUBSTITUTED PHENYL-PIPERAZINE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-07-06 | — | — | WO | disclosed |
| EP-1676842-A1 | Nitro-substituted phenyl-piperazine compounds, their preparation and use in medicaments | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-07-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110218200-A1 | METHODS OF TREATING AMYLOID DISEASE USING ANALOGS OF 1-(4-NITROPHENYL) PIPERAZINE | PSEN1, PSEN2, APP | HTR6 1377/4885MAPT 10/4885CYP1A2 4025/4885 |
| US-20100120747-A1 | COMBINATION OF A CHOLINESTERASE INHIBITOR AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | HTR6, AANAT, ACHE | HTR6 1/4885MAPT 1416/4885CYP1A2 1090/4885 |
| US-20100074955-A1 | Combination of NMDA-Receptor Ligand and a Compound With 5-HT6 Receptor Affinity | GRM6, GRIN3B, GRIN3A | HTR6 4/4885MAPT 1966/4885CYP1A2 4406/4885 |
| US-20080176854-A1 | Nitro-Substituted Phenyl-Piperazine Compounds, Their Preparation and Use in Medicaments | HTR6, HTR5A, P2RX5 | HTR6 1/4885MAPT 3000/4885CYP1A2 227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.